Autoimmune retinopathy with RPE hypersensitivity and 'negative ERG' in X-linked hyper-IgM syndrome

Ocular Immunology and Inflammation

Volumn 13, Issue 2-3, 2005, Pages 235-243

  Schuster, Andreas ^a   Apfelstedt Sylla, Eckart ^a   Pusch, Carsten M ^b   Zrenner, Eberhart ^a   Thirkill, Charles E ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR; PROTEIN; TNFSF5IP1 PROTEIN, HUMAN;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CHROMOSOME DELETION; DISEASE ASSOCIATION; ELECTROPHYSIOLOGY; ELECTRORETINOGRAM; GENETIC ANALYSIS; GENOTYPE; HUMAN; HYPERGAMMAGLOBULINEMIA; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD STEM CELL; PIGMENT EPITHELIUM; POLYMERASE CHAIN REACTION; RETINOPATHY; SEQUENCE TAGGED SITE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION; X CHROMOSOME LINKED DISORDER; ELECTRORETINOGRAPHY; GENETICS; HYPERSENSITIVITY; IMMUNE DEFICIENCY; IMMUNOLOGY; MUTATION; RETINA DISEASE;

ADOLESCENT; AUTOIMMUNE DISEASES; ELECTRORETINOGRAPHY; GENETIC DISEASES, X-LINKED; HUMANS; HYPERGAMMAGLOBULINEMIA; HYPERSENSITIVITY; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MUTATION; PIGMENT EPITHELIUM OF EYE; POLYMERASE CHAIN REACTION; PROTEINS; RETINAL DISEASES; VISUAL ACUITY; VISUAL FIELDS;

EID: 25144501233     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940590928571     Document Type: Article

References (50)

1. Ramesh N, Seki M, Notarangelo LD, et al. The hyper-IgM (HIM) syndrome. Springer Semin Immunopathol. 1998;9:383-399.
2. Hadzic N, Pagliuca A, Rela M, et al. Correction of the hyper-IgM syndrome after liver and bone marrow transplantation. N Engl J Med. 2000;342:321-324.
3. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. 1997;131:47-54.
4. Schonbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol. 2000;32:687-689.
5. Pilia G, Porta G, Padayachee M, et al. Human CD40L gene maps between DXS144E and DXS300 in Xq26. Genomics. 1994;22:249-255.
6. Alien RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993;259:990-993.
7. Noelle RJ, Meenakshi R, Shepherd DM, et al. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acac Sci USA. 1992;89:6550-6554.
8. Keltner JL, Thirkill CE. The 22-kDa antigen in optic nerve and retinal diseases. J Neuro-Ophthalmol. 1999;19:71-83.
9. Jacobson DM. Paraneoplastic diseases of neuro-ophthalmologic interest. In: Miller NR, Newman NJ, editors. Walsh & Hoyt's clinical neuro-ophthalmology. 5th ed. Baltimore: Williams & Wilkins, 1998;2497-2551.
10. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976;81:606-613.
11. Thirkill CE, Roth AM, Keltner JL. Cancer-associated retinopathy. Arch Ophthalmol. 1987;105:372-375.
12. Keltner JL, Thirkill CE. Cancer-associated retinopathy vs recoverin-associated retinopathy. Am J Ophthalmol 1998;126:296-302.
13. Vaphiades MS, Brown H, Whitcup SM. Node way out: Comments by Keltner JL, Thirkill CE. Surv Ophthalmol. 2000;45:77-83.
14. Weinstein JM, Kelman SE, Bresnick GH, et al. Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology. 1994;101:1236-1243.
15. Potter MJ, Thirkill CE, Dam OM, et al. Clinical and immunocytochemical findings in a case of melanoma-associated retinopathy. Ophthalmology. 1999;106:2121-2125.
16. Mizener JB, Kimura AE, Adamus G, et al. Autoimmune retinopathy in the absence of cancer. Am J Ophthalmol. 1997;123:607-618.
17. Cogan DG, Kuwabara T, Currie J, et al. Paraneoplastic retinopathy simulating cone dystrophy with achromatopsia. Klin Monatsbl Augenheilkd, 1990;197:156-158.
18. Thirkill CE, Keltner JL, Tyler NK, et al. Antibody reactions with retina and cancer-associated antigens in 10 patients with cancer-associated retinopathy. Arch Ophthalmol. 1993;111:931-937.
19. Thirkill CE, Tait RC, Tyler NK, et al. The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci. 1992;33:2768-2772.
20. Milam A, Dacey DM, Dizhoor AM. Recoverin immunoreactivity in mammalian cone bipolar cells. Vis Neurosci. 1993;10:1-12.
21. Polans AS, Burton MD, Haley TL, et al. Recoverin, but notvisinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34:81-90.
22. Heckenlively JR, Fawzi AA, Oversier J, et al. Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration. Arch Ophthalmol. 2000;118:1497-1507.
23. Whitcup SM, Vistica BP, Milam AH, et al. Recoverin-associated retinopathy: a clinically and immunologically distinctive disease. Am J Ophthalmol. 1998;126:230-237.
24. Thirkill CE, Tait RC, Tyler NK, et al. Intraperitoneal cultivation of small-cell carcinoma induces expression of the retinal cancer-associated retinopathy antigen. Arch Ophthalmol. 1993;111:974-978.
25. Peek R, Dijkstra BG, Meek B, et al. Autoantibodies to photoreceptor membrane proteins and outer plexiform layer in patients with cancer-associated retinopathy. Clin Exp Immunol. 2002;128:498-503.
26. Thirkill CE. Retinal pigment epithelial hypersensitivity, an association with vision loss: RPE hypersensitivity complicating paraneoplastic retinopathies. Ocul Immunol Inflamm. 2000;8:25-37.
27. Milam AH, Saari JC, Jacobson SG, et al. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci. 1993;34:91-100.
28. Alexander KR, Fishman GA, Peachey NS, et al. On response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci. 1992;33:477-483.
29. Miyake Y, Yagasaki K, Horiguchi M, et al. Congenital stationary night blindness with negative electroretinogram: a new classification. Arch Ophthalmol. 1986;104:1013.
30. Keltner JL, Thirkill CE, Yip PT Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuro-Ophthalmol. 2001;21:173-187.
31. To KW, Thirkill CE, Jacobiec FA, et al. Lymphoma-associated retinopathy. Ophthalmology. 2002;109:2149-2153.
32. Cheng LL, Kwok AK, Wat NM, et al. Graft-vs-host-disease-associated conjunctival chemosis and central serous chorioretinopathy after bone marrow transplant. Am J Ophthalmol. 2002;134:293-295.
33. Marmor MF, Zrenner E. Standard for clinical electroretinography (1999 update). Doc Ophthalmol. 1999;97:143-156.
34. Sutter EE, Tran D. The field topography of ERG components in man. I. The photopic luminance response. Vision Res. 1992;32:433-446.
35. Marmor MF, Zrenner E. Standard for clinical electro-oculography. International Society for Clinical Electrophysiology of Vision. Arch Ophthalmol. 1993;111:601-604.
36. Sieving PA. Photopic on- and off-pathway abnormalities in retinal dystrophies. Trans Am Ophthalmol Soc. 1993;81:701-773.
37. Keltner JL, Thirkill CE, Tyler NK, et al. Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol. 1992;110:48-53.
38. Peek R.Verbraak F, Coevoet HMN, et al. Müller cell-specific autoantibodies in a patient with progressive loss of vision. Invest Ophthalmol Vis Sci. 1998;39:1976-1979.
39. Chant SM, Heckenlively J, Meyers-Elliott RH. Autoimmunity in hereditary retinal degeneration. I. Basic studies. Br J Ophthalmol. 1985;69:19-24.
40. Thirkill CE, Roth AM, Takemoto DJ, et al. Antibody indications of secondary and superimposed retinal hypersensitivity in retinitis pigmentosa. Am J Ophthalmol, 1991;121:132-137.
41. Gurne DH, Tso MOM, Edward DP, et al. Antiretinal antibodies in serum of patients with age-related macular degeneration. Ophthalmology. 1991;98:602-607.
42. Isashiki Y, Ohba N, Nakagawa M, et al. Antibodies against human retinal proteins in serum from patients with cone dystrophy. Jpn J Ophthalmol. 1992;36:323-330.
43. Ebner R, DaCol E, Bullorsky E. True, true and related? Surv Ophthalmol. 2001;45:489-492.
44. Franklin RM, Kenyon KR, Tutschka PJ, et al. Ocular manifestations of graft-vs-host disease. Ophthalmology. 1983;90:4-13.
45. Lopez PF, Sternberg P, Dabbs CK, et al. Bone marrow transplant retinopathy. Am J Ophthalmol. 1991;112:635-646.
46. Han DP, Simons KB, Tarkanian CN, et al. Endophthalmitis from Mycobacterium bovis-bacille Calmette-Guerin after intravesicular bacille Calmette-Guerin injections for bladder carcinoma. Am J Ophthalmol. 1999;128:648-650.
47. Wertheim M, Astbury N. Bilateral uveitis after intravesical BCG Immunotherapy for bladder carcinoma. Br J Ophthalmol. 2002;86:706.
48. Hirose S, Tanaka T, Nussenblatt RB, et al. Lymphocyte responses to retinal-specific antigens in uveitis patients and healthy subjects. Curr Eye Res. 1988;7:393-402.
49. Gregerson DS, Dou C. Spontaneous induction of immunoregulation by an endogenous retinal antigen. Invest Ophthalmol Vis Sci. 2002;43:2984-2991.
50. Yamauchi H, Iso T, Uda K. The role of lysosomal enzymes in adjuvant-induced uveitis in rabbits. Nippon Yakurigaku Zasshi. 1979;75:185-190.